Literature DB >> 22863387

Subclinical hyperfunctioning pituitary adenomas: the silent tumors.

Odelia Cooper1, Shlomo Melmed.   

Abstract

Pituitary adenomas are classified by function as defined by clinical symptoms and signs of hormone hypersecretion with subsequent confirmation on immunohistochemical staining. However, positive immunostaining for pituitary cell types has been shown for clinically nonfunctioning adenomas, and this entity is classified as silent functioning adenoma. Most common in these subtypes include silent gonadotroph adenomas, silent corticotroph adenomas and silent somatotroph adenomas. Less commonly, silent prolactinomas and thyrotrophinomas are encountered. Appropriate classification of these adenomas may affect follow-up care after surgical resection. Some silent adenomas such as silent corticotroph adenomas follow a more aggressive course, necessitating closer surveillance. Furthermore, knowledge of the immunostaining characteristics of silent adenomas may determine postoperative medical therapy. This article reviews the incidence, clinical behavior, and pathologic features of clinically silent pituitary adenomas.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22863387      PMCID: PMC3412996          DOI: 10.1016/j.beem.2012.01.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  93 in total

Review 1.  POU-domain transcription factors: pou-er-ful developmental regulators.

Authors:  M G Rosenfeld
Journal:  Genes Dev       Date:  1991-06       Impact factor: 11.361

2.  NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene.

Authors:  G Poulin; B Turgeon; J Drouin
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

3.  Dax-1 as one of the target genes of Ad4BP/SF-1.

Authors:  K Kawabe; T Shikayama; H Tsuboi; S Oka; K Oba; T Yanase; H Nawata; K Morohashi
Journal:  Mol Endocrinol       Date:  1999-08

4.  Clinically silent corticotroph tumors of the pituitary gland.

Authors:  B W Scheithauer; A J Jaap; E Horvath; K Kovacs; R V Lloyd; F B Meyer; E R Laws; W F Young
Journal:  Neurosurgery       Date:  2000-09       Impact factor: 4.654

5.  Developmental dependence on NurRE and EboxNeuro for expression of pituitary proopiomelanocortin.

Authors:  Pierre-Luc Lavoie; Lionel Budry; Aurélio Balsalobre; Jacques Drouin
Journal:  Mol Endocrinol       Date:  2008-04-03

Review 6.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

7.  A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas.

Authors:  Shozo Yamada; Kenichi Ohyama; Manabu Taguchi; Akira Takeshita; Koji Morita; Koji Takano; Toshiaki Sano
Journal:  Neurosurgery       Date:  2007-09       Impact factor: 4.654

8.  Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).

Authors:  Alberto Fernandez; Niki Karavitaki; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2009-07-24       Impact factor: 3.478

9.  Expression of an orphan nuclear receptor DAX-1 in human pituitary adenomas.

Authors:  S Ikuyama; Y M Mu; K Ohe; H Nakagaki; T Fukushima; R Takayanagi; H Nawata
Journal:  Clin Endocrinol (Oxf)       Date:  1998-05       Impact factor: 3.478

10.  Differential gene expression in ACTH -secreting and non-functioning pituitary tumors.

Authors:  Toru Tateno; Hajime Izumiyama; Masaru Doi; Takanobu Yoshimoto; Masayoshi Shichiri; Naoko Inoshita; Kenichi Oyama; Shozo Yamada; Yukio Hirata
Journal:  Eur J Endocrinol       Date:  2007-12       Impact factor: 6.664

View more
  25 in total

Review 1.  Silent somatotroph pituitary adenomas: an update.

Authors:  Fabienne Langlois; Randall Woltjer; Justin S Cetas; Maria Fleseriu
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 2.  [New aspects of tumor pathology of the pituitary].

Authors:  W Saeger
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

Review 3.  Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.

Authors:  Luis V Syro; Fabio Rotondo; Carlos A Serna; Leon D Ortiz; Kalman Kovacs
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 4.  Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Chris G Yedinak; Isabelle Cetas; Shirley McCartney; Justin Cetas; Aclan Dogan; Maria Fleseriu
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

5.  Aggressive somatotrophinomas lacking clinical symptoms: neurosurgical management.

Authors:  Mario Giordano; Amir Samii; Rudolf Fahlbusch
Journal:  Neurosurg Rev       Date:  2017-12-30       Impact factor: 3.042

Review 6.  Management of non-functioning pituitary adenomas: surgery.

Authors:  David L Penn; William T Burke; Edward R Laws
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

7.  Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Elena Varlamov; Chris G Yedinak; Justin S Cetas; Shirley McCartney; Aclan Dogan; Maria Fleseriu
Journal:  Endocrine       Date:  2017-10-17       Impact factor: 3.633

8.  Early postoperative growth in non-functioning pituitary adenomas; A tool to tailor safe follow-up.

Authors:  Kristin Astrid Øystese; Manuela Zucknick; Olivera Casar-Borota; Geir Ringstad; Jens Bollerslev
Journal:  Endocrine       Date:  2017-05-17       Impact factor: 3.633

Review 9.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

Review 10.  Non-functioning pituitary adenomas: growth and aggressiveness.

Authors:  Kristin Astrid Øystese; Johan Arild Evang; Jens Bollerslev
Journal:  Endocrine       Date:  2016-04-11       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.